Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy

Type de document :
Communication dans un congrès
the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. Annals of Oncology, Volume 28, Issue suppl_5, 28 (suppl_5), 2017, Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8–12 September 2017, Madrid, Spain. 〈https://academic.oup.com/annonc/article/28/suppl_5/mdx369.155/4108858/773TiPPRODIGE-51-GASTFOX-Phase-III-randomised〉. 〈10.1093/annonc/mdx393.007〉
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01632524
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : vendredi 10 novembre 2017 - 12:47:38
Dernière modification le : vendredi 8 juin 2018 - 14:50:25

Lien texte intégral

Identifiants

Citation

C. Gallois, J. Taieb, D. Le Corre, K. Le Malicot, J. Tabernero, et al.. Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy . the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. Annals of Oncology, Volume 28, Issue suppl_5, 28 (suppl_5), 2017, Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8–12 September 2017, Madrid, Spain. 〈https://academic.oup.com/annonc/article/28/suppl_5/mdx369.155/4108858/773TiPPRODIGE-51-GASTFOX-Phase-III-randomised〉. 〈10.1093/annonc/mdx393.007〉. 〈hal-01632524〉

Partager

Métriques

Consultations de la notice

25